Trial Profile

Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Entrectinib (Primary) ; Goserelin (Primary) ; Letrozole (Primary)
Indications Early breast cancer; HER2 negative breast cancer
Focus Biomarker; Therapeutic Use
Acronyms ROSALINE

Most Recent Events

02 Dec 2024 Planned End Date changed from 1 Oct 2024 to 1 Jan 2025.
02 Dec 2024 Planned primary completion date changed from 1 Aug 2024 to 1 Jan 2025.
12 Jun 2024 Planned End Date changed from 1 Jul 2024 to 1 Oct 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com